Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Randomised Study on Liposomal Cytarabine (DepoCyte) vs. Intrathecal Triple for CNS-Treatment During Maintenance Therapy in High-Risk Acute Lymphoblastic Leukemia Patients in NOPHO ALL 2008 Treatment Protocol.

Next Previous
Trial Profile

Phase III Randomised Study on Liposomal Cytarabine (DepoCyte) vs. Intrathecal Triple for CNS-Treatment During Maintenance Therapy in High-Risk Acute Lymphoblastic Leukemia Patients in NOPHO ALL 2008 Treatment Protocol.

Status: Suspended
Phase of Trial: Phase III

Latest Information Update: 18 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cytarabine (Primary) ; Asparaginase; Dexamethasone; Mercaptopurine; Methotrexate; Prednisolone sodium succinate
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use

Most Recent Events

  • 21 Jun 2020 Results of an analysis from following clinical trials: Dutch: DCOG-ALL10/11 trials, Australian: ANZCHOG-ALL8 and AIEOP-BFM-ALL2009 trials, UK: ALL2003 trial and NOPHO-ALL2008 trial assessing association between Down syndrome and clinical outcome presented at the 25th Congress of the European Haematology Association
  • 02 May 2016 This trial is 'prematurely ended' in Lithuania, according to European Clinical Trials Database.
  • 17 Mar 2012 Additional location (Lithuania) added and additional lead trial centre identified as reported by European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top